The present disclosure relates to a composition for preventing, treating or remedying female climacteric syndrome symptoms, which contains tectorigenin 7-O-xylosylglucoside. The composition according to the present disclosure shows quick effects for preventing, remedying and/or treating female climacteric syndrome symptoms, particularly facial flushing and/or osteoporosis, and thus can be utilized for the hormone replacement therapy (HRT) used for preventing or remedying climacteric syndrome symptoms.

Provided are compounds, pharmaceutical compositions, cosmetic and dermatological compositions or nutritional supplement compositions, comprising omega-3 very-long-chain polyunsaturated fatty acids (n-3 VLC-PUFAs) and/or their endogenous hydroxylated derivatives thereof, known as elovanoids. This disclosure provides methods for neuroprotection, organ and tissue protection or restoration, prevention or slowing down of aging-related diseases and conditions, and sustainment of function during the aging process.

Provided are compounds, pharmaceutical compositions, cosmetic and dermatological compositions or nutritional supplement compositions, comprising omega-3 very-long-chain polyunsaturated fatty acids (n-3 VLC-PUFAs) and/or their endogenous hydroxylated derivatives thereof, known as elovanoids. This disclosure provides methods for neuroprotection, organ and tissue protection or restoration, prevention or slowing down of aging-related diseases and conditions, and sustainment of function during the aging process.

A xanthophyll composition that contains macular pigments including trans-lutein and zeaxanthin isomers, namely, (R,R)-zeaxanthin and (R,S)-zeaxanthin, derived from the plant extract/oleoresin containing xanthophylls/xanthophylls esters which is safe for human consumption and useful for nutrition and health care. The composition has at least 80% by weight that is total xanthophylls, of which the ratio of trans-lutein and zeaxanthin isomers being in the range of about 4:1 to about 6:1 and the ratio of the isomers of zeaxanthin being in the range of about 80 to 20:20 to 80.

A xanthophyll composition that contains macular pigments including trans-lutein and zeaxanthin isomers, namely, (R,R)-zeaxanthin and (R,S)-zeaxanthin, derived from the plant extract/oleoresin containing xanthophylls/xanthophylls esters which is safe for human consumption and useful for nutrition and health care. The composition has at least 80% by weight that is total xanthophylls, of which the ratio of trans-lutein and zeaxanthin isomers being in the range of about 4:1 to about 6:1 and the ratio of the isomers of zeaxanthin being in the range of about 80 to 20:20 to 80.

Methods for enhancing joint function and for treating or preventing age-related joint discomfort in an adult human are disclosed. The methods comprise administering to the human a dietetic food, medical food, or food supplement. The food or food supplement comprises a rumenic acid-rich conjugated linoleic acid (RAR-CLA), or a pharmaceutically acceptable salt, ester, mono-, di-, or triglyceride, metabolic precursor thereof, or mixture thereof, in an amount effective to enhance joint function or to alleviate joint discomfort in the human. The RAR-CLA comprises cis-9, trans-11 linoleic acid and trans-10, cis-12 linoleic acid isomers in a weight ratio of at least 2:1. Enrichment of a dietetic food, medical food, or food supplement with RAR-CLA can help to improve joint function and/or alleviate joint discomfort. Longer-term studies should help to further elucidate the potential impact of RAR-CLA supplementation on joint function in older adults.

Methods for enhancing joint function and for treating or preventing age-related joint discomfort in an adult human are disclosed. The methods comprise administering to the human a dietetic food, medical food, or food supplement. The food or food supplement comprises a rumenic acid-rich conjugated linoleic acid (RAR-CLA), or a pharmaceutically acceptable salt, ester, mono-, di-, or triglyceride, metabolic precursor thereof, or mixture thereof, in an amount effective to enhance joint function or to alleviate joint discomfort in the human. The RAR-CLA comprises cis-9, trans-11 linoleic acid and trans-10, cis-12 linoleic acid isomers in a weight ratio of at least 2:1. Enrichment of a dietetic food, medical food, or food supplement with RAR-CLA can help to improve joint function and/or alleviate joint discomfort. Longer-term studies should help to further elucidate the potential impact of RAR-CLA supplementation on joint function in older adults.

Combination of dry extract of Rhodiola, dry extract of Trubulus terrestris, dry extract of Undaria pinnatifida, Moringa oleifera, folic acid and vitamin B12 in the form of food supplement for mitigating woman's disorders caused by ageing.

Combination of dry extract of Rhodiola, dry extract of Trubulus terrestris, dry extract of Undaria pinnatifida, Moringa oleifera, folic acid and vitamin B12 in the form of food supplement for mitigating woman's disorders caused by ageing.

The invention provides methods for mimicking chronic caloric restriction to impart a health benefit in an animal or for using an intermittent partially restricted diet to impart a health benefit to an animal. Such methods can include feeding an animal two different diets having differing caloric contents in a specific ratio to achieve such benefits.